Table 1 Baseline patient characteristics and treatment
From: Obstructive voiding symptoms following stereotactic body radiation therapy for prostate cancer
|  |  | % Patients (N = 269) |
|---|---|---|
Age (y/o) | Median 69 (44-90) | Â |
| Â | <60 | 8.2% |
| Â | 60-69 | 42.4% |
| Â | 70-79 | 41.3% |
|  | ≥80 | 8.2% |
Race | Â | Â |
| Â | White | 55.8% |
| Â | Black | 37.2% |
| Â | Other | 7.1% |
Baseline PSA (ng/dL) | Median 6.2 (0.2-32.5) | Â |
Prostate Volume (cc) | Median 39.04 (11.56-138.69) | Â |
IPSS Baseline | Median 8 (0-33) | Â |
|  | Mild (≤7) | 49.3% |
| Â | Moderate (8-19) | 45.5% |
|  | Severe (≥20) | 5.2% |
Procedure for BPH prior to RT | Â | Â |
| Â | Yes | 10.0% |
| Â | No | 90.0% |
α 1A Antagonist Utilization |  |  |
| Â | Yes | 32.1% |
| Â | No | 67.9% |
Risk Group | Â | Â |
| Â | Low | 36.8% |
| Â | Intermediate | 53.2% |
| Â | High | 10.0% |
Hormonal Therapy | Â | Â |
| Â | Yes | 16.4% |
| Â | No | 83.6% |
Dose | Â | Â |
| Â | 36.25Â Gy | 83.3% |
| Â | 35Â Gy | 16.4% |
| Â | Other | 0.4% |